Navigation Links
Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2010 Financial Results
Date:11/10/2010

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it will hold a conference call to discuss financial results for the third quarter ended September 30, 2010. The conference call is scheduled for November 11, 2010 at 1:00 p.m. Eastern time (10:00 a.m. Pacific).

To participate in the call, please dial (877) 941-1430, or (480) 629-9667 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found at http://ViaVid.net.

A replay of the call will be available for two weeks from 4:00 p.m. EST on November 11, 2010 until 11:59 p.m. EST on November 25, 2010. The number for the replay is (877) 870-5176, or (858) 858-384-5517 for international calls; the pass code for the replay is 4385128.

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comInvestor Relations:Dave Gentry, U.S.RedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 104Email: info@redchip.comJing Zhang, ChinaRedChip Beijing Representative OfficeTel: +86 10-8591-0635Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
2. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
3. Lotus Pharmaceuticals Announces Two Senior Management Appointments
4. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
5. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
6. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
7. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
8. Lotus Pharmaceuticals Terminates SEDA
9. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
10. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
11. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech Fund ...
(Date:5/3/2016)... Ore. , May 3, 2016   BIOTRONIK ... importance of extending care beyond the implant at the ... May 4-7 in San Francisco . ... continually delivering the highest quality of patient care and ... are cared for each and every tomorrow," said ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER ... and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all ... May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Nike Rugby ... junior rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike ... and players every year since 2009. , “I’m excited for our eighth summer ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... surgery at their office. Wisdom tooth removal, a common dental procedure, is performed for ... often are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental business ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and driving ... her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in both ...
Breaking Medicine News(10 mins):